Table 5. Responses and surgery type segregated according to the outcomes from primary hormone therapy.
| Drug (References) | Patients n | Clinical response | Mammography | Echography | Conservative surgery |
|---|---|---|---|---|---|
| Letrozole | 124 | 74 (60%) | 47 (37%) | 48 (39%) | 60 (48%) |
| Tamoxifen (Eiermann et al, 2001) | 126 | 52 (41%) | 25 (20%) | 37 (29%) | 45 (36%) |
| P<0.001 | <0.001 | P=0.042 | P=0.022 | ||
| Anastrozole | 113 | 42 (37%) | 27 (24%) | 21/46 (46%) | |
| Anastrozole+Tamoxifen | 109 | 31 (28%) | 11/42 (26%) | ||
| Tamoxifen (Smith et al, 2005) | 108 | 39 (36%) | 22 (20%) | 8/36 (22%) | |
| P=n/s | P=n/s | P A vs T=0.03 | |||
| Exemestane | 36 | 32 (88%) | 24 (67%) | 25 (69%) | 14 (39%) |
| Tamoxifen (Semiglazov et al, 2005) | 37 | 19 (51%) | 15 (40%) | 15 (40%) | 4 (11%) |
| P=n/s | P=n/s | P=0.088 | P<0.05 | ||
| Exemestane (Astner et al, 2004) | 29 | 10 (35%) | 14 (48%) | ||
| Exemestane (current study) | 54 | 33 (61%) | 23 (51%) | 18 (51.4%) | 21 (56%)a |
Clinical response: objective clinical response (partial and complete remission are included). Conservative surgery: patients undergoing conservative surgery.
a
Only 43 patients underwent surgical treatment.